Document:

<PAGE>
                                                                   EXHIBIT 10.35

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                  CONFIDENTIAL

                                SUPPLY AGREEMENT

                                     between

                            Boehringer Mannheim GmbH
                             Sandhofer Strasse 116
                                 68305 Mannheim
                                     Germany
                        (hereinafter referred to as "BM")

                                       and

                             Gen-Probe Incorporated
                           10210 Genetic Center Drive
                                    San Diego
                                CA 92121-4362 USA
                    (hereinafter referred to as "GEN-PROBE")

<PAGE>

PREAMBLE

      GEN-PROBE desires to purchase from BM and BM desires to sell to GEN-PROBE
      certain raw materials for Transcription Mediated Amplification ("TMA")
      related diagnostic units.

      In order to provide for the supply of the Products to GEN-PROBE, both
      parties agree on the following:

SECTION 1 DEFINITIONS

1.1   "Products" shall mean those raw materials included in Categories A and B
      unless otherwise agreed by the parties in writing:

      CATEGORY A

            1.)   recombinant Moloney murine leukemia virus reverse
                  transcriptase; and

            2.)   recombinant bacteriophage T7 RNA Polymerase.

      CATEGORY B

            1.)   deoxyribonucleotides (dGTP, dTTP, dATP, dCTP);

            2.)   ribonucleotides (ATP, CTP, GTP, UTP);

            3.)   proteinase K; and

            4.)   zwittergent,

      in accordance with functional specifications and acceptance criteria as
      set forth in Attachment A hereto, for the Intended Use. Within thirty (30)
      days of the date of this Agreement, BM shall provide to Gen-Probe: (1) a
      description of each BM test method identified in Attachment A; and (2) the
      specifications for each Product identified by BM catalog number in
      Attachment A.

      With regard to T7 RNA Polymerase, the parties expect that the initial
      specification set forth in Attachment A will be modified by GEN-PROBE and
      mutually agreed upon within 180 days of the date of this Agreement. BM
      agrees not to unreasonably withhold consent to such modified specification
      for the T7 RNA Polymerase.

                                     Page 1
<PAGE>

1.2   "Intended Use" shall mean the use of the Products by GEN-PROBE in
      connection with developing and producing Transcription-Mediated
      Amplification related diagnostic products wherein Products meeting the
      specifications set forth in Attachment A are appropriate for use.

1.3   "Affiliates" of either party shall mean any corporation, partnership
      organization which such party directly or indirectly controls, is
      controlled by or is under common control with. For the purpose of this
      Agreement, "Control" shall mean the holding of 50% or more of the voting
      stock or other ownership interest of the corporation or business entity
      involved.

1.4   "Transformed Clone" shall mean a recombinant Moloney murine leukemia virus
      reverse transcriptase clone, which was originally provided by GEN-PROBE to
      BM, to the extent the original clone was modified or genetically
      transformed by BM, using BM's confidential know how, for the purpose of
      optimizing fermentation processes and characteristics. (The "Transformed
      Clone" includes the material internally labeled by [***].) GEN-PROBE
      acknowledges that it consented to and approved BM's modification of the
      original clone, using BM's confidential know how, for the purpose of
      optimizing fermentation processes and characteristics for GEN-PROBE's
      exclusive benefit.

SECTION 2 SUBJECT MATTER OF THE AGREEMENT

2.1   The subject matter of this Agreement is the terms and conditions for the
      supply of the Products by BM to GEN-PROBE.

2.2   The Products shall be manufactured and/or distributed by BM or its
      Affiliates and shall conform to the specifications and acceptance criteria
      set forth in Attachment A. No changes shall be made to the specifications
      and acceptance criteria without the prior written approval of both
      parties, which shall not be unreasonably withheld.

2.3   During the term of this Agreement GEN-PROBE shall purchase from BM and BM
      shall supply to GEN-PROBE the minimum percentage of the worldwide usage by
      GEN-PROBE for the Intended Use, as shown in Attachment C.

2.4   Gen-Probe shall, upon request by BM, provide documentation, reasonably
      satisfactory to BM, verifying compliance with Section 2.3.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 2
<PAGE>

2.5   BM shall not make any change to its processes or procedures which may
      alter any Product's stability or performance. BM shall provide notice of
      any proposed change in its processes or procedures in accordance with
      certified ISO procedures for change control applicable to in vitro
      diagnostic raw material. BM's notice shall include a full description of
      the proposed change. GEN-PROBE shall be provided with sufficient samples
      of any Product made by a process which will be subject to the proposed
      change to enable GEN-PROBE to determine that such Product(s) will meet
      specifications and will function in Gen-Probe's TMA products.

SECTION 3 TERMS OF DELIVERY

3.1   The Products shall be delivered F.O.B destination, priority shipment.

3.2   Each delivery shall be accompanied by a release certificate by the quality
      control laboratory of BM, confirming that the shipment conforms to the
      specifications and acceptance criteria set forth in Attachment A and
      setting forth the results of BM's quality control tests pursuant to the
      test methods described in Attachment A.

SECTION 4 PURCHASE PRICE

4.1   (a) Fixed Prices to be paid by GEN-PROBE for the Products are specified in
          Attachment B through the year 2004 and are contingent upon current
          specifications and acceptance criteria as described in Attachment A.

      (b) If acceptance criteria or specifications for the Products are changed
          at GEN-PROBE's request, the prices are subject to change to the extent
          necessary to compensate BM for such changes. The prices are also
          subject to change pursuant to Section 9.2 of this Agreement,
          concerning regulatory requirements.

                                     Page 3
<PAGE>

      (c) If, at any time after the first anniversary date of this Agreement,
          the U.S. Dollar - Deutsch Mark exchange rate (or the U.S. Dollar -
          Euro exchange rate, if applicable), is more than 15% higher or lower
          than the date existing on the date of this Agreement, then either
          party may request that revised prices be negotiated to reflect such
          change. The parties shall negotiate revised prices in good faith and
          each party shall be entitled to take into account the economic impact
          of the proposed change on its own interests. If despite good faith
          negotiations, new prices cannot be agreed upon within ninety (90) days
          following a request by either party, the party requesting the price
          revision may terminate this Agreement upon ninety (90) days written
          notice.

4.2   BM may, after the seventh (7th) anniversary of this agreement and subject
      to the restrictions in the next two (2) sentences, adjust the purchase
      prices in Attachment B to incorporate actual changes in the raw materials
      and labor costs associated with the manufacture of the Products. [***]. BM
      shall provide GEN-PROBE not less than one hundred and twenty (120) days
      prior written notice of any proposed increase in the purchase price of the
      Products. GEN-PROBE and BM agree to negotiate any such price changes in
      good faith and with the intent of seeking a mutually beneficial
      resolution. The increase in the price of any Product shall not exceed
      [***] of the prior year's purchase price for that Product.

4.3   Upon written request by a party, the other party shall provide
      documentation supporting any proposed price adjustment requested under the
      terms of this Agreement to a mutually agreeable certified public
      accountant who shall review the aforementioned documentation for
      supporting the price adjustment. The certified public accountant shall
      sign a secrecy agreement with the party providing the information and
      shall act regarding the provided information in accordance with such
      secrecy agreement. The certified public accountant shall only make a
      statement whether the provided documentation supports the proposed price
      adjustment or not.

4.4   The Product purchase price in any year shall be estimated by applying
      GEN-PROBE's purchase order pursuant to Section 7.1 for that year to the
      appropriate pricing tier schedule in Attachment B.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 4
<PAGE>

      If the amount of any Product actually purchased by GEN-PROBE in any year
      is more or less than that estimated and as a result a different pricing
      tier schedule applies to the amount actually purchased, then not later
      than sixty (60) days after the first anniversary and each anniversary
      thereafter, the parties shall reconcile the effect on the purchase price
      for that Product in the preceding year caused by any shortfall or overage
      in the total quantity of the Product actually purchased, and any payment
      due as a result of such reconciliation shall be made by the appropriate
      party within 30 days.

SECTION 5 PAYMENT

      GEN-PROBE shall pay each BM invoice for Product(s) within thirty (30) days
      of the date of invoice. BM will invoice GEN-PROBE no earlier than the date
      BM ships the Products described in the invoice to GEN-PROBE. Invoicing and
      payment shall be made in US dollars.

SECTION 6 FORECASTING PROCESS

6.1   GEN-PROBE has set forth its initial estimates of its anticipated purchase
      projection from BM in Attachment C. BM understands that these estimates
      are not binding, except for 1998, and do not establish any minimum amount
      of purchases by GEN-PROBE.

      For purposes of BM's long term manufacturing capacity planning, GEN-PROBE
      shall provide to BM annually by the last day of September, a revised
      projection of purchase volume for each of the succeeding three (3)
      calendar years or for the remaining period of the contract, whichever
      period is shorter. Each year BM and GEN-PROBE shall agree on the quantity
      of the Products to be delivered in the next year for any Product as to
      which GEN-PROBE ordered more than twice the projected amount for the
      preceding year. The lead time to adjust BM's manufacturing capacity to
      said quantity will be negotiated and agreed upon following agreement with
      the new projection. All such estimates shall be considered to be
      confidential and proprietary information of GEN-PROBE under this
      Agreement.

SECTION 7 PURCHASE ORDERS, DELIVERY PROCESS AND SECURITY OF SUPPLY

7.1   GEN-PROBE shall submit to BM by the last day of September of each year a
        purchase order of its requirements for the Products for the next
        succeeding year. Each of GEN-PROBE's purchase orders for the Products
        shall be in writing and shall constitute a binding obligation upon
        GEN-PROBE to accept and pay for a minimum of [***] of the quantities
        ordered. In conjunction with its annual purchase order, GEN-PROBE shall
        provide to BM, in writing, a

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 5
<PAGE>

      quarterly delivery schedule which identifies quantities, destinations, and
      approximate delivery dates.

      Furthermore, both parties will agree annually in December of each calendar
      year on adequate levels of safety stock and storage locations therefor to
      ensure the agreed upon terms of delivery are achieved. The parties agree
      that a significant portion of the safety stocks shall be maintained at
      GEN-PROBE's facility at San Diego, California and the balance at BM's
      facilities in the United States. As to any Products kept as safety stocks
      at Gen-Probe's facilities, BM shall provide the information described in
      Section 3.2 for such Products at the timof the delivery of those Products
      into the safety stock. GEN-PROBE shall not be obligated to pay for the
      safety stock Products except (1) upon use of such Products; (2) Pursuant
      to Section 13.4; or (3) To the extent that GEN-PROBE requests that more
      than a 90-day supply of Products be stored in San Diego as part of the
      safety stock.

      Additional provisions concerning the logistical arrangements for the
      safety stock and creation of the initial safety stock shall be agreed by
      the parties within 120 days of the date of this Agreement. It is the
      parties' present intent that the safety stock shall include an amount of
      each of the Products equal to GEN-PROBE's requirements for a six-month
      period.

7.2   Proposed additions to the agreed upon annual purchase quantities
      identified in the annual purchase order shall be submitted by GEN-PROBE in
      writing to BM.

      BM will use reasonable efforts to meet delivery times of ninety (90) days
      from date of receipt of quantity changes. Delivery dates for quantities
      outside of planned volumes will be negotiated at the time the written
      change request is received.

7.3   As compensation for BM's R&D expenses, GEN-PROBE has committed to purchase
      the Products and their stated amounts as set forth in Attachment C for the
      year 1998.

7.4   Gen-Probe and BM have previously entered into a material transfer
      agreement with respect to the transfer of reverse transcriptase clones
      from GEN-PROBE to BM and certain research and development work by BM. The
      provisions of any prior material transfer agreement between the parties
      are hereby superseded with respect to use of the Transformed Clone and
      ownership and use of any intellectual property of BM reflected or
      incorporated in the Transformed Clone. All other provisions of the
      material transfer agreements shall remain in effect.

                                     Page 6
<PAGE>

      BM shall be solely and exclusively entitled to use and make Transformed
      Clones. Notwithstanding the preceding sentence, GEN-PROBE may use the
      Transformed Clone in accordance with the provisions set forth below in
      this Section 7.4. GEN-PROBE shall not be entitled to use the Transformed
      Clone in any manner or on any terms other than those set forth below in
      this Section 7.4.

      Immediately following the signing of this Agreement, and from time-to-time
      thereafter if appropriate, BM shall deliver to GEN-PROBE examples of the
      Transformed Clone, which sample shall be treated as and kept confidential
      in accordance with paragraph 12 of this Agreement.

      (A)   USE OF THE TRANSFORMED CLONE BY GEN-PROBE DURING TERM OF AGREEMENT
            SO LONG AS BM IS ABLE TO SUPPLY GEN-PROBE WITH REVERSE
            TRANSCRIPTASE.

            During the term of this Agreement and so long as BM is able to
            supply GEN-PROBE with transformed reverse transcriptase, GEN-PROBE
            agrees that it will not, without the prior express written consent
            of BM, do any of the following:

            (1)   [***]

            (2)   [***]

            (3)   [***]

            (4)   [***]

            (5)   [***]

            (6)   [***]

            During the term of this Agreement and so long as BM is able to
            supply GEN-PROBE with transformed reverse transcriptase, GEN-PROBE
            may only use the Transformed Clone for the following specific
            purposes:

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 7
<PAGE>

            (1)   [***]

            (2)   [***]

            (3)   [***]

      (B) USE OF TRANSFORMED CLONE UPON FAILURE OF BM TO SUPPLY.

            In the event that BM fails to supply Gen-Probe with reverse
            transcriptase in accordance with this Agreement, BM may use a third
            party supplier as necessary for securing the supply of reverse
            transcriptase. The use of the aforementioned third party supplier by
            BM is subject to prior written consent by GEN-PROBE, which consent
            shall not unreasonably withheld. The third party shall sign a
            material transfer agreement with BM and with GEN-PROBE regarding the
            Transformed Clones which shall, among such other things as may be
            provided by BM, protect and preserve GEN-PROBE's rights in the
            Transformed Clone and GEN-PROBE's confidential materials and
            information. The Third Party shall receive the Transformed Clones
            and the know how with regard to the fermentation and the
            purification and shall return the Transformed Clones and the know
            how with regard to the fermentation and the purification to BM
            promptly after BM has become able to supply GEN-PROBE with reverse
            transcriptase. If a third party supplier is not found by BM within
            three (3) months after the event of non-supply has occurred, then
            GEN-PROBE may, at its option, assign a third party supplier (which
            assignment is subject to prior written consent of BM, which consent
            shall not unreasonably withheld), or after seeking such a third
            party supplier may terminate this Agreement. The third party shall
            sign a material transfer agreement with BM and with GEN-PROBE
            regarding the Transformed Clones, shall receive the Transformed
            Clones and the know how with regard to the fermentation and the
            purification and shall return the Transformed Clones and the know
            how with regard to the fermentation and the purification to BM
            promptly after GEN-PROBE has had a reasonable opportunity to arrange
            for an alternative source of supply, not to exceed three years.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 8
<PAGE>

      (C) USE OF TRANSFORMED CLONE UPON TERMINATION OF AGREEMENT.

            After expiration or termination of this Agreement for any reason
            whatsoever, GEN-PROBE shall not use the Transformed Clone except
            upon obtaining a non-exclusive royalty bearing license from BM to
            use BM's know how incorporated in the transferred Transformed Clone
            and in the field and territory as set forth in the this Agreement in
            order to continue the manufacture of reverse transcriptase required
            to manufacture TMA related diagnostic units by GEN-PROBE. (The
            foregoing sentence is subject to GEN-PROBE'S rights as set forth in
            subsection 7.4(B) above.)

            BM hereby grants an option to GEN-PROBE for such a license. The
            option shall be exercised by GEN-PROBE within sixty (60) days after
            expiration or termination of this Agreement. GEN-PROBE shall not use
            the know-how to be licensed by BM for purposes other than those
            described in this section and described in the license agreement.
            The royalty to be paid and the other terms and conditions of the
            license agreement shall be negotiated between BM and GEN-PROBE in
            good faith and shall not exceed commercially reasonable terms
            reflecting the terms charged by others for comparable technology.
            The annual royalties to be agreed upon, however, shall not exceed an
            annual amount of [***] of the Average of the Total Sales of the
            reverse transcriptase which average total sales shall be calculated
            of the calendar year of the termination or expiration and the two
            (2) preceding calendar years. If this Agreement is terminated within
            three (3) years upon execution of this Agreement, the annual
            royalties to be agreed upon shall not exceed an annual amount of
            [***] of the total sales of the reverse transcriptase in the
            calendar year preceding the termination. If this Agreement is
            terminated during the first calendar year upon execution the annual
            royalties to be agreed upon shall not exceed an annual amount of
            [***] of the total sales of the reverse transcriptase in the
            calendar year of termination.

            The license to be granted hereunder shall not authorize GEN-PROBE to
            conduct research to [***] in any GEN-PROBE development work.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 9
<PAGE>
SECTION 8 ACCEPTANCE

      GEN-PROBE shall, within thirty (30) days upon receipt of any shipment,
      inspect The Products to determine whether or not the delivery conforms to
      the applicable specifications and acceptance criteria. GEN-PROBE shall
      promptly give BM written notice of any failure or nonconformity. If
      GEN-PROBE fails to notify BM of any nonconformity of any Product within
      forty-five (45) days of receipt of the Product, GEN-PROBE shall be deemed
      to have accepted that Product as properly shipped and suitable for the
      Intended Use, except as to the stability specification for any Product, as
      to which GEN-PROBE shall be deemed to have accepted the Product if it does
      not give written notice within 30 days of discovery of the failure of the
      Product to meet the stability specification.

SECTION 9 REGULATORY MATTERS

9.1   A Design History File (DHF), Device Master Record (DMR), and Device
      History Record (DHR) shall be kept by BM at its premises for all Category
      A Products and for all deoxyribonucleotides and ribonucleotides and shall
      be available to the FDA directly or confidentially through a third party
      for necessary regulatory inspections. If the aforementioned documents have
      to be filed at the FDA the costs of this filing shall be paid by
      GEN-PROBE. To the extent that BM reasonably incurs significant costs for
      complying with the requirements of this Section as to deoxyribonucleotides
      and ribonucleotides, the parties will negotiate in good faith to
      compensate BM for such costs and to define a reasonable time period for
      completion of such requirements.

9.2   If the applicable regulatory agencies request amendments of the
      documentation or design of the Products including but not limited to DHF,
      DMR and DHR, BM undertakes to use its reasonably best efforts to fulfill
      these requirements. Any such amendments shall be mutually agreed upon
      between GEN-PROBE and BM. The parties shall agree upon compensation to BM
      in connection with fulfilling the requirements of the amendments before
      any action is taken, unless such amendments are the result of BM's failure
      to comply with manufacturing standards requiring utilization of such
      manufacturing processes as are controlled and validated, with adequate
      records of the processes used. To the extent that adequate compensation
      for such proposed changes cannot be provided to BM by way of reasonable
      adjustment to the purchase price of the Products, the parties will
      negotiate in good faith for another form of payment to BM. If the parties
      are not able to agree on such compensation, either party may terminate
      this Agreement.

                                    Page 10
<PAGE>
SECTION 10 INTELLECTUAL PROPERTY RIGHTS

10.1  The ownership of any and all intellectual property rights of BM as
      reflected in the Transformed Clone and BM's T7 RNA Polymerase shall remain
      with BM. BM recognizes that the Transformed Clone is a derivative of an
      original clone supplied to BM by GEN-PROBE and BM therefore agrees not to
      transfer the Transformed Clone to any other person or entity (with the
      exception of affiliates of BM or subcontractors appointed by BM and
      authorized by GEN-PROBE, which affiliates and subcontractors shall have
      the same secrecy obligations as the Parties with regard to the original
      GEN-PROBE clone and the Transformed Clone).

10.2  In the Event that claim of patent infringement is made against BM or any
      of its Affiliates, by any third party by reason of GEN-PROBE's sale or use
      of the Products in combination with GEN-PROBE technology, to the extent
      that the infringement is based upon the new combination product, GEN-PROBE
      hereby agrees to indemnify, defend and save each of them, harmless of and
      from and all liability, loss, cost, injury, damage, demand and expense
      (including, without limitation, reasonable attorney's fees) of any kind
      whatever arising out of, on account of, or in connection with such claim
      of infringement. Excepted from such hold harmless obligation shall be
      indirect or consequential damages whether or not based on negligence.

      In the event that claim of patent infringement is made against GEN-PROBE
      or any of its Affiliates, by any third party by reason of GEN-PROBE's sale
      or use of the Products, BM hereby agrees to indemnify, defend and hold
      GEN-PROBE, and its parents, subsidiaries, Affiliates, officers, directors,
      agents and employees, and each of them, harmless of and from any and all
      liability, loss, cost, injury, damage, demand and expense (including,
      without limitation, reasonable attorney's fees) of any kind whatsoever
      arising out of, on account of, or in connection with such claim of
      infringement. Excepted from such hold harmless obligation shall be
      indirect or consequential damages whether or not based on negligence.

10.3  BM and GEN-PROBE agree to give prompt written notice to the other of the
      commencement of any action, suit or proceeding for which the foregoing
      indemnification may be sought, and the other party, through counsel
      reasonably satisfactory to BM or GEN-PROBE, shall assume the defense
      thereof. It is agreed that the party claiming a right to indemnification
      shall be entitled to participate in any such action, suit or proceeding
      with counsel of its own choice, but at its own expense.

                                    Page 11
<PAGE>
SECTION 11 WARRANTY AND LIABILITY

11.1  BM hereby warrants that the Products will be produced in accordance with
      the applicable regulations and statutory requirements, will fully conform
      to the Product specifications listed in Attachment A hereto, and will be
      free from defects in materials or workmanship. BM's manufacturing
      processes shall meet the requirements of any manufacturing standards
      applicable to materials included or used in the manufacture of in vitro
      diagnostic products of like kind as GEN-PROBE's TMA products, but not less
      than such manufacturing processes as are controlled and validated, with
      adequate records of the processes used. If BM incurs additional costs in
      order to meet standards imposed after the Signing Date of this Agreement,
      the prices charged pursuant to Section 4 are subject to change to the
      extent necessary to compensate BM for such changes. To the extent that
      adequate compensation for such proposed changes cannot be provided to BM
      by way of reasonable adjustment to the purchase price of the Products, the
      parties will negotiate in good faith for another form of payment to BM. If
      the parties are not able to agree on such compensation, either party may
      terminate this Agreement.

      Beyond the warranties expressly stated herein, BM shall assume no warranty
      as to the fitness of the Products for the purpose intended by GEN-PROBE.

      THE FOREGOING WARRANTY SHALL BE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS
      OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WAY OF
      MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO CASE SHALL BM
      BE LIABLE FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES.

      The financial liability of BM in connection with its warranty obligations
      under this Section 11.1 shall be limited to the reimbursement or crediting
      of the price of the defective Products to GEN-PROBE or, where this may be
      agreed between the Parties hereto, to the supply of the Products in
      replacement for the defective Products. Nothing in this Section shall
      limit GEN-PROBE's rights under Section 11.2.

11.2  BM will defend, indemnify and hold harmless GEN-PROBE from any and all
      claims, liabilities or reasonable out-of-pocket expenses arising from or
      related to any and all claims and will pay all cost of damages finally
      awarded in any proceedings or any settlement made with BM's consent with
      respect to any claims for damages alleged to have been sustained as a
      result of BM's negligent acts or omissions. Excepted from such hold
      harmless obligation shall be indirect or consequential damages whether or
      not based on negligence.

                                     Page 12
<PAGE>
      GEN-PROBE will defend, indemnify and hold harmless BM from any and all
      claims, liabilities or reasonable out-of-pocket expenses arising from or
      related to any and all claims and will pay all cost of damages finally
      awarded in any proceedings or any settlement made with GEN-PROBE's consent
      with respect to any claims for damages alleged to have been sustained as a
      result of GEN-PROBE's negligent acts or omissions. Excepted from such hold
      harmless obligation shall be indirect or consequential damages whether or
      not based on negligence.

      Any liability of BM or GEN-PROBE under this Section 11.2 shall be limited
      to [***].

11.3  Each party agrees to promptly give written notice to the other party of
      the commencement of any action, suit or proceeding for which
      indemnification may be sought, and the indemnifying party, through counsel
      reasonably satisfactory to the indemnified party shall assume the defense
      thereof. It is agreed, however, that the indemnified party shall be
      entitled to participate in any such action, suit or proceeding with
      counsel of its own choice, but at its own expense.

SECTION 12 SECRECY OBLIGATION

      Each party shall keep all information and know how communicated to it or
      otherwise obtained from the other party at any time during the term of
      this Agreement and in connection with this Agreement (including but not
      limited to know-how, technology, pricing, usage rates, and business
      projections) secret and confidential and shall not disclose the same or
      any part thereof to any third party. Excepted herefrom is information:

      a)    which is in the public domain at the time of disclosure,

      b)    which is published or otherwise becomes part of the public domain
            through no fault of the party receiving the information,

      c)    which was in the possession of the receiving party at the time of
            disclosure, as shown by prior written records, or becomes available
            from a third party who has the right to disclose it;

      d)    which is required to be communicated to authorities or customers for
            the purpose of sale of the Products, or

      e)    which has been independently developed by the receiving party at or
            before the date of disclosure.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                     Page 13

<PAGE>
SECTION 13 TERM AND TERMINATION

13.1  This Agreement becomes effective as of the date of signature of the last
      party to sign and shall remain in force for an initial period of ten (10)
      years from the execution of this Agreement. Thereafter the Agreement
      automatically prolongs for two (2) year terms if not terminated by one of
      the parties at the end of the initial period or prolongation period with
      twelve (12) months prior written notice.

13.2  In the event that either party fails or becomes unable to substantially
      perform any of the obligations or undertakings to be performed by it under
      this Agreement then the other party shall provide the defaulting party
      with written notification of such default. If such default or inability
      is not cured within ninety (90) days to the mutual satisfaction of both
      parties, then the non-defaulting party shall have the right to terminate
      this Agreement upon 15 days upon written notice. Notwithstanding the
      foregoing provisions, if BM's default is limited only to an inability to
      deliver, within ten (10) working days after the scheduled delivery date on
      the purchase order, any single Product, then GEN-PROBE shall be obligated
      to first use one-half of the then-available safety stock of that Product
      established pursuant to section 7.1 of this Agreement, and -- after using
      one-half of the safety stock of that Product -- then GEN-PROBE shall only
      have the right to partially terminate this Agreement as to the single
      Product which BM has failed to deliver.

13.3  Both parties shall have the right to terminate this Agreement forthwith in
      the event that the other party shall become bankrupt or insolvent, or make
      any arrangement with its creditors and/or a winding-up order is made and/
      or if its business shall be placed in the hands of a receiver, assignee or
      trustee, whether by the voluntary act or otherwise.

      All rights granted hereunder by BM to its intellectual property or
      confidential information under any title whatsoever, except for the rights
      set forth in Section 7.4 B and C, shall return to BM after termination or
      expiration of this Agreement.

13.4  After any termination of the Agreement (except for a termination by
      GEN-PROBE due to BM's failure to meet Product specifications or due to
      BM's intentional and willful default), GEN-PROBE shall purchase from BM
      the complete existing safety stock of the Products at the prices as agreed
      upon between BM and GEN-PROBE for the last full year in which The Products
      have been sold. BM shall provide the information described in Section 3.2
      for the safety stock Products at the time of the delivery of those
      Products. As to any Products which are kept as safety stocks at a
      GEN-PROBE facility, GEN-PROBE shall accept or reject such Products
      pursuant to Section 8 of this Agreement within 30 days of the initial
      delivery of such Products to GEN-PROBE for use as safety stock.

                                     Page 14
<PAGE>
13.5  Upon the termination of this Agreement, BM shall destroy all Transformed
      Clones. Upon the termination of this Agreement, Gen-Probe shall destroy
      all Transformed Clones except to the extent it has continuing rights with
      respect to the Transformed Clone under Section 7.4 of this Agreement.

13.6  The following provisions shall survive termination of this Agreement:
      Sections 4, 5, 7.4, 10, 11, 12, 13.4, 14 and 15.

SECTION 14 ARBITRATION

      Any controversy, claim or dispute existing out of or relating to this
      Agreement, or the breach thereof, shall be resolved by binding
      arbitration, with any proceedings or hearings to take place rendered by
      arbitration may be entered in any Court having jurisdiction. If parties do
      not agree upon location, the arbitrator shall determine the location. If
      arbitration is necessary pursuant to this paragraph, the Parties shall
      agree upon a single arbitrator. If the Parties are unable to agree on an
      arbitrator, then they will obtain nominations of three potential
      arbitrators from the International Chamber of Commerce of New York, USA
      and each party will have the right to strike one candidate's name from the
      list. The International Chamber of Commerce of New York, USA will then
      designate the arbitrator. Any arbitration award shall also include, but
      shall not be limited to, any and all court or arbitration costs, attorney
      fees and any other costs or charges reasonably necessary to adjudicate the
      controversy, in addition to any and all damages deemed fair by the
      arbitrator. Nothing contained herein shall deprive any party of his or her
      right to obtain injunctive or other equitable relief.

SECTION 15 GENERAL PROVISIONS

15.1  Entire Agreement

      This Agreement constitutes the entire understanding between the parties
      with respect to the subject matter hereof, and supersedes and replaces all
      prior agreements, understandings, writings and discussions between the
      parties relating to said subject matter, except as to any and all prior
      material transfer or confidential disclosure agreements between the
      parties, which are superseded only with respect to the Transformed Clone
      in the manner expressly set forth in Sections 1.4, 7.4, and 10.1.

                                     Page 15
<PAGE>
15.2  Amendments; Waivers

      This Agreement may be amended and any of its terms or conditions may be
      waived only by a written instrument executed by both parties, or, in the
      case of a waiver, by the party waiving compliance. The failure of either
      party at any time to require performance of any provision hereof shall in
      no manner affect its rights at a later time to enforce the same. No waiver
      by either party of any condition or term in any instance shall be
      construed as a further or continuing waiver of such condition or term or
      of another condition or term.

15.3  Successors and Assigns

      This Agreement shall be binding upon and inure to the benefit of and be
      enforceable by the parties hereto and their respective successors and
      permitted assigns. BM shall be entitled to assign this Agreement if
      necessary after the merger with Hoffmann-La Roche to its succeeding legal
      entity with the exception that no GEN-PROBE-designated proprietary
      information shall be disclosed to competing operating business units
      affiliated with BM, including Hoffman-La Roche.

15.4  Governing Law

      This Agreement will be in all events and for all purposes governed by, and
      construed in accordance with the law of the State of Indiana.

15.5  Severability

      The parties agree that if any part, term or provision of this Agreement
      shall be found illegal or in conflict with any valid controlling law, the
      validity of the remaining provisions shall not be affected thereby.

      In the event the legality of any provision of this Agreement is brought
      into question because of a decision by a Court of competent jurisdiction
      of any country in which this Agreement applies, GEN-PROBE and BM will
      negotiate in good faith in order to revise or delete the provision in
      question so as to comply with the decision of said Court.

      In the event that the terms and conditions of this Agreement are
      materially altered as a result of the preceding sub-paragraphs, the
      Parties shall re-negotiate the terms and conditions of this Agreement in
      order to resolve any inequities.

                                     Page 16
<PAGE>
15.6  Headings and titles in this Agreement are for convenience purposes only
      and shall not in any way influence the construction, performance and
      enforcement of any of its provisions.

15.7  Written Notices required to be given under this Agreement shall be
      considered duly given upon receipt by the addressee if mailed by first
      class registered mail with return receipt requested, postage prepaid and
      addressed as follows:

      If to BM:

         Boehringer Mannheim GmbH
         Legal Counsel, Biochemical Division
         Sandhofer Strasse 116
         68305 Mannheim
         Germany

If to GEN-PROBE:

         Gen-Probe Incorporated
         Attention: General Counsel
         10210 Genetic Center Drive
         San Diego, California, U.S.A. 92121-4362

15.8  Force Majeure

      In the event that either party is prevented from performing or is unable
      to perform any of its obligations due to any act of God, war, labor
      difficulties, riot, fire, flood, hurricane, wind storm, failure of public
      utilities, acts of default by common carriers, governmental laws, act or
      regulations (including withdrawal or suspension of governmental sale of
      Product), shortages of materials or any other occurrence beyond the
      control of the party affected thereby, if such party shall have used its
      best effort to avoid such occurrence, such party shall give notice to the
      other promptly in writing, and thereupon the affected party's performance
      shall be excused and the time for performance shall be extended for the
      period of the delay or inability to perform due to such occurrence;
      provided always that upon BM's inability to supply any Product, GEN-PROBE
      shall have the right, after using one-half of the safety stock of any
      affected Product(s), to obtain such Product(s) from an alternative source
      and to exercise its rights under section 7.4 if necessary.

                                     Page 17
<PAGE>
15.9  The following attachments to this Agreement are hereby incorporated into
      this Agreement by this reference and shall be considered integral parts of
      this Agreement.

Attachment A:   Specifications and Product
                Acceptance Criteria

Attachment B:   BM Product Pricing Schedule

Attachment C:   Annual Product Projections

      IN WITNESS WHEREOF, the parties have signed this Agreement, which shall be
effective on a date that it is signed by the last party to sign (the "Signing
Date").

Mannheim, Germany                        San Diego, California U.S.A.
March 5, 1998                            March 2, 1998

Boehringer Mannheim GmbH                 Gen-Probe Incorporated

By: /s/ FRED RUSH                        By: /s/ HENRY L. NORDHOFF
    ---------------------------              -----------------------------------
    Fred Rush                                Henry L. Nordhoff
    Senior Vice President                    President and
                                             Chief Executive Officer

By: /s/ JAN VAN DER VALK
    --------------------------
    Jan van der Valk
    Senior Director Legal Counsel

                                    Page 18
<PAGE>

              ATTACHMENT A: SPECIFICATIONS AND ACCEPTANCE CRITERIA

    [44 Pages of Specifications and Product Information Deleted Pursuant to
                        Confidential Treatment Request]

<PAGE>
                            Attachment B, Category A

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>
                            Attachment B, Category B

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                  Attachment C

                                     [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.<PAGE>
                                                                   EXHIBIT 10.43

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                               AMENDMENT NO. 3 TO
                                   AGREEMENT

     This Amendment No. 3 ("AMENDMENT NO. 3") is entered effective April 1,
2002 (the "AMENDMENT EFFECTIVE DATE") pursuant to and amending that certain
Agreement (as defined below) between Gen-Probe Incorporated, a Delaware
corporation ("GEN-PROBE") and Chiron Corporation, a Delaware corporation
("CHIRON"), on behalf of itself and its Affiliates. Capitalized terms used but
not defined herein shall have the meanings set forth in the Agreement.

                                    Recitals

     A.   The parties entered into the Agreement as of June 11, 1998 pursuant to
which, among other things, the parties described their respective rights and
obligations with respect to production planning and inventory management
processes. The Agreement was amended by the following: (i) June 11, 1998
Collaboration Agreement, (ii) June 11, 1998 Supplemental letter agreement, (iii)
June 26, 1998 Addendum to Collaboration Agreement, (iv) June 30, 1998
Supplemental letter agreement, (v) June 30, 1998 Consent, (vi) December 1, 1998
letter agreement re American Red Cross revenues, (vii) December 7, 1999 First
amendment to Collaboration Agreement, (viii) February 1, 2000 Second amendment
to Collaboration Agreement, (ix) June 7, 2001 Supplemental agreement no. 1
(Customer training and Support), (x) October 30, 2001 Confidentiality and Joint
Interest Agreement, (xi) April 4, 2001 Agreement re Arbitration. In addition,
the parties entered into that certain Definitive Written Settlement Agreement
dated December 4, 2001 (the "Settlement Agreement").

     B.   The parties have discussed a proposed revision to and clarification of
their respective rights and obligations with respect to production planning and
inventory management processes, and have agreed to make certain additional
changes to the Agreement in connection therewith, in accordance with the
provisions of this Amendment No. 3.

     C.   By this Amendment No. 3, the parties desire to revise and clarify
their respective rights and obligations, as described herein, applicable to all
Blood Screening Assays, including one or more Future Blood Screening Assays to
be conducted by the Blood Screening Instruments to be developed under the terms
of the Agreement.

                                   Agreement

     NOW, THEREFORE, for and in consideration of the mutual covenants and
agreements set forth in this Amendment No. 3, the parties agree as follows:

     1.   DEFINITIONS.

          1.1  "Agreement" means that certain Agreement entered into as of June
11, 1998 by and between Gen-Probe Incorporated, a Delaware corporation with a
principal place of business at 10210 Genetic Center Drive, San Diego CA 92121
and Chiron Corporation, a Delaware corporation, with a place of business at
4560 Horton Street, Emeryville, CA 94608, on behalf of itself and its
Affiliates, as amended by the amendments referenced in Recital A above.

          1.2  "Settlement Agreement" means that certain Definitive Written
Settlement Agreement dated December 5, 2001 executed by and between Chiron
Corporation and Gen-Probe Incorporated.

                                       1
<PAGE>
          1.3  "Supplemental Agreement" means that certain Supplemental
Agreement No. 2 dated December 5, 2001 executed by and between Chiron
Corporation and Gen-Probe Incorporated.

          1.4  The following definitions shall be added to the Agreement, for
the purpose of the amendments made by this Amendment No. 3, by adding the
following subsections to Section 1 of the Agreement:

     "1.60 "Customer" means the Third Party to whom Blood Screening Assays are
     sold, transferred or otherwise conveyed by Chiron, its Affiliates or the
     Major Distributor.

     1.61 "Forecast" means the twelve-month rolling forecast of Chiron's
     estimated purchase requirements of Blood Screening Assays over the period
     covered by the forecast, as set forth in Section 6.3.1 of the Agreement, as
     amended pursuant to this Amendment No. 3.

     1.62 "Lot" means each of Gen-Probe's manufacturing lots of Blood Screening
     Assays.

     1.63 "Purchase Order" means the binding purchase order of Blood Screening
     Assays delivered in accordance with the provisions of Section 6.3.3 of the
     Agreement, as amended pursuant to this Amendment No. 3."

     2.   FORECASTS AND ORDERS.    Section 6.3 of the Agreement and its
associated subsections are hereby deleted and replaced in their entirety with
the following:

     "6.3 Forecasts and Orders.

          6.3.1     Forecasts.

                    (a)  On or before the first (1st) day of each calendar month
     during the term of this Agreement, Chiron shall provide to Gen-Probe a
     Forecast, covering the period commencing the calendar month immediately
     succeeding the month in which the Forecast is delivered (for example, on
     January 1, Chiron will deliver a rolling twelve (12) month, showing
     Chiron's estimated purchase requirements over the period covered by the
     Forecast. The Forecast shall include purchase requirements, at the
     following level of detail:

                         (i)   for the first (1st), second (2nd) and third (3rd)
     calendar months covered by the Forecast, the Forecast shall specify the
     Blood Screening Assays by packaging configuration, including kit size
     and/or catalogue part number, and associated quantities for purchase from
     Gen-Probe by Chiron in such three-month period;

                         (ii)  for the  fourth (4th), fifth (5th) and sixth
     (6th) calendar months covered by the Forecast, the Forecast shall specify
     the Blood Screening Assays and ancillary materials, by labeling requirement
     detailed according to the provisions of Schedule A.1, attached hereto, and
     associated quantities that Chiron expects to order from Gen-Probe by Chiron
     in such period; and

                         (iii) for the seventh (7th) through twelfth (12th)
     calendar months covered by the Forecast, the Forecast shall specify the
     estimated purchase requirements, by test, and associated quantities that
     Chiron expects to order from Gen-Probe by Chiron in such period.

                         (iv)  Subject to the additional provisions set forth in
     subparagraph (v) below, in each Forecast delivered, Chiron may not (A)
     amend the quantities of Blood Screening Assays from the quantities
     specified for the first (1st), second (2nd) and third (3rd) calendar months

                                       2

<PAGE>

in the immediately preceding Forecast; (B) amend the quantities of Blood
Screening Assays specified in the Forecast for the fourth (4th), fifth (5th) and
sixth (6th) calendar months in the immediately preceding Forecast to an amount
that is less than [***] nor more than [***] of the amount forecasted when the
month being amended was the sixth (6th) calendar month; (C) amend the quantities
of Blood Screening Assays specified in the Forecast for the seventh (7th)
calendar month in the immediately preceding Forecast as it transitions to the
sixth (6th) calendar month in the delivered Forecast to an amount that is less
than [***] nor more than [***] of the quantity of Blood Screening Assays
specified in the previous Forecast when the month in question was the seventh
(7th) calendar month; or (D) amend the quantities of Blood Screening Assays
specified in the Forecast for the eighth (8th) calendar month in the immediately
preceding Forecast as it transitions to the seventh (7th) calendar month in the
delivered Forecast to an amount that is less than [***] nor more than [***] of
the quantity of Blood Screening Assays specified in the previous Forecast when
the month in question was the eighth (8th) calendar month. For example, on
January 1, Chiron will deliver a Forecast in which February is the first (1st)
calendar month and September is the eighth (8th) calendar month of the Forecast.
If Chiron estimates in such Forecast that in August, the seventh (7th) calendar
month, it will require [***] tests, Chiron may not decrease its Forecast below
[***] tests nor increase it above [***] tests as that month transitions to the
sixth (6th) calendar month in the next Forecast. Similarly, if Chiron estimates
in a Forecast that in September, the eighth (8th) calendar month, it will
require [***] tests, then in the subsequent Forecast Chiron may not decrease its
Forecast below [***] tests nor increase it above [***] tests when that month
transitions to the seventh (7th) calendar month. For purpose of the convenience
of reference hereafter, the Forecast delivered in which the applicable calendar
month is the eighth (8th) month is referred to as the "original Forecast"; and
the quantity as forecast in any subsequent Forecast, amended as permitted under
this Section (i.e. the Forecast delivered in which the applicable month
transitions to the next lower month, such as from the eighth (8th) month to the
seventh (7th)), is referred to as the "amended Forecast."

            (v) Notwithstanding the provisions of subparagraph (iv) above, the
parties acknowledge that Gen-Probe incurs substantial expense ramping up
production and otherwise preparing to meet quantities forecasted by Chiron, even
in periods commencing the seventh (7th) calendar month and beyond in the
then-current Forecast. Therefore, the parties agree that Chiron may NOT reduce
the Forecast DOWN under subparagraph (iv)(B) and (C), above, in the aggregate to
an amount that is less than [***] of the highest quantity of Blood Screening
Assays specified in any Forecast. (For example, on January 1, Chiron will
deliver a Forecast in which February 1 is the first (1st) month and September is
the eighth (8th) month of the Forecast. If Chiron estimates in such Forecast
that in September it will require [***] tests, then Chiron may not amend the
Forecast, at any time or in the aggregate, to an amount that is less than [***]
tests deliverable in September. In addition, if, in the subsequent Forecast when
the month in question transitions from the eighth (8th) to the seventh (7th)
month, Chiron increases the Forecast of the month in question from [***] tests
to [***] tests, then Chiron may not amend the Forecast to an amount that is less
than [***] tests deliverable in September (i.e. [***]). Similarly, if in the
next Forecast, when the month in question transitions from the seventh (7th) to
the sixth (6th) month, Chiron further increases the Forecast to [***] tests,
then Chiron may not amend the Forecast to an amount that is less than [***]
tests deliverable in September (i.e. [***]).)

      (b) Commencing in the first full month following the Amendment Effective
Date, the parties shall meet monthly, on or before the twenty-second (22nd) day
of each calendar month, to review the previous month's performance and the
current Forecast and production plan

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                       3
<PAGE>

for the purpose of making production planning and inventory management
decisions necessary to meet Customer supply needs in a cost-efficient manner.
Such production planning meetings shall be attended by qualified members of
each party, and shall be sponsored by Chiron's Director of Global Supply Chain
Management and Gen-Probe's Vice-President of Manufacturing - Blood Products.
The parties shall implement a standing agenda in the form set forth in Schedule
A.2, attached hereto, and may consider such additional information as is agreed
upon by both parties.

            (c)   In the event that any disagreement arises between the parties
pursuant to the obligations imposed in this Section 6.3.1, the parties shall
submit such dispute first to a discussion between responsible managers, and if
they cannot agree, then to the Supervisory Board for resolution as soon as is
reasonably achievable. In the event that the Supervisory Board is (i) unable to
resolve the issue at its next meeting, or (ii) is unable or unwilling to meet
within the thirty (30) day period after submittal of the issue to the
Supervisory Board, then the issue shall be referred by the parties for
resolution in accordance with the terms of Article 13 herein.

      6.3.2 Purchase Obligation.

            (a)   Chiron shall be required to purchase, in the respective month,
the quantity of Blood Screening Assays, by part number, specified in each
Forecast for the first (1st), second (2nd) or third (3rd) covered by each
Forecast. If any Forecast fails to conform to with the provisions of Section
6.3.1, considered in the aggregate, then for purposes of determining Chiron's
purchase obligation under this Section 6.3.2(a) such non-conforming Forecast
shall be revised to comply with such provisions of Section 6.3.1.

            (b)   Notwithstanding anything in this Agreement to the contrary,
the expiration or sooner termination of this Agreement, other than a termination
by Chiron for default of Gen-Probe in accordance with the provisions of Section
11.2.1 and subject to the provisions of Section 15.2 governing force majeure
events, shall not operate to extinguish Chiron's obligation to purchase the
quantity of Blood Screening Assays specified in accordance with Section 6.3.1
through the eighth (8th) calendar month covered by the Forecast in effect as
of the effective date of expiration or sooner termination.

            (c)   In the event that any disagreement arises between the parties
pursuant to the obligations imposed in this Section 6.3.2, the parties shall
submit such dispute first to a discussion between responsible managers, and if
they cannot agree, then to the Supervisory Board for resolution as soon as is
reasonably achievable. In the event that the Supervisory Board is (i) unable to
resolve the issue at its next meeting, or (ii) is unable or unwilling to meet
within the thirty (30) day period after submittal of the issue to the
Supervisory Board, then the issue shall be referred by the parties for
resolution in accordance with the terms of Article 13 herein.

      6.3.3 Purchase Orders.

            (a)   Chiron shall submit to Gen-Probe a binding Purchase Order on
or before the fifth (5th) day of each calendar month during the term hereof
covering the Blood Screening Assays forecasted by Chiron for the third (3rd)
calendar month covered by the then-current Forecast (for example, on January 5,
Chiron will submit a Purchase Order for Blood Screening Assays to be delivered
in April). Each Purchase Order shall be in writing and reasonably similar to the
sample Purchase Order attached hereto as Schedule A.3. Each Purchase Order shall
specify the quantity of Blood Screening Assays ordered (by packaging
configuration, including kit size and/or catalogue part number), the place of
delivery, the requested delivery date, and such other information as Gen-Probe
reasonably requests. Chiron may not request a delivery date for any Blood
Screening Assays that is less than eighty-five (85) days or more than
ninety-five (95) days after the date of the applicable Purchase Order (for
example, a Purchase Order submitted to

                                       4

<PAGE>
Gen-Probe on January 5 may only specify a delivery date between the first and
the tenth of April).

               (b)  Purchase Orders submitted to Gen-Probe by Chiron shall be
binding on Gen-Probe as to that quantity of Blood Screening Assays set forth in
the then-current Forecast for such calendar month. If the quantity of any Blood
Screening Assays ordered by Chiron for any calendar month exceeds the quantity
of such Blood Screening Assays set forth in the then-current Forecast for such
month, then Gen-Probe shall use Commercially Reasonable Efforts to deliver the
amount of Blood Screening Assays in excess of the forecasted amount. Gen-Probe
shall provide Chiron with written notice of the anticipated delivery date for
such additional Blood Screening Assays.

               (c)  In the event that any Purchase Order received from Chiron
herein fails to order Blood Screening Assays of the types and in the amounts
specified in the then-current Forecast for the applicable calendar month,
Gen-Probe shall have the right to reject such Purchase Order(s). Gen-Probe shall
notify Chiron in writing within ten (10) days of receipt of such Purchase
Order(s). If not rejected by Gen-Probe within ten (10) days of receipt, such
Purchase Order(s) shall be deemed accepted by Gen-Probe. In the event that
Gen-Probe rejects a purchase order Chiron shall have 5 days to correct the
purchase order and resubmit it to Gen-Probe.

               (d)  In the event that any disagreement arises between the
parties pursuant to the obligations imposed in this Section 6.3.3, the parties
shall submit such dispute first to a discussion between responsible managers,
and if they cannot agree, then to the Supervisory Board for resolution as soon
as is reasonably achievable. In the event that the Supervisory Board is (i)
unable to resolve the issue at its next meeting, or (ii) is unable or unwilling
to meet within the thirty (30) day period after submittal of the issue to the
Supervisory Board, then the issue shall be referred by the parties for
resolution in accordance with the terms of Article 13 herein.

               (e)  In the event of a conflict between the terms and conditions
of any Purchase Order and this Agreement, the terms and conditions of this
Agreement shall prevail.

     6.3.4     Inventory.

     (a)       The parties agree that the amount of inventory sufficient to
ensure uninterrupted testing by Customers in the event of a disruption of supply
of Blood Screening Assays from Gen-Probe is a minimum of (5) months' forward
demand for such Blood Screening Assays, as determined by the most current
Forecast. Accordingly, Chiron shall purchase and maintain a minimum of a five
(5) months inventory of Blood Screening Assays based on the latest Chiron
Forecast. The five (5) months inventory will be maintained at Chiron's
warehousing facilities (which facilities are set forth in Schedule A.4 attached
hereto). As Chiron develops greater visibility of customer inventory, Chiron has
the right to reduce its inventory by including the inventory held at the
customer sites. However, Chiron must ensure that the inventory level held by
Chiron (taking into account up to (5) months' inventory that Chiron can show is
held by each customer) is sufficient to always supply each customer with a
minimum of 5 months' supply. Prior to reducing their inventory, Chiron must
submit their inventory plan to the Supervisory Board for review and approval.

               (b)  Notwithstanding the foregoing, Gen-Probe shall maintain
sufficient inventory of raw materials and work in progress as necessary to meet
the production requirements for Chiron's commitments for the first through
eighth months of Chiron's most current Forecast.

               (c)  Each party shall give an independent certified public
accounting firm selected by the other party access to the applicable records
(and the applicable records of any Affiliate or Major Distributor) for the
purpose of permitting the audit, at the auditing party's

                                       5
<PAGE>

expense and in accordance with Section 7.3 of this Agreement, of compliance
with this Section 6.3.4.

      6.3.5 Supply Obligation.

            (a)   Gen-Probe shall be required to supply in any given month the
quantity of Blood Screening Assays ordered by Chiron pursuant to a Purchase
Order as to that quantity of Blood Screening Assays set forth in the
then-current Forecast for such month, as the forecasted demand may be amended as
permitted in Section 6.3.1(a)(iv) above. If Gen-Probe becomes aware of any fact
indicating that Gen-Probe may be unable to meet Chiron's forecasted demand as
specified in the original Forecast as to any Blood Screening Assay or indicating
that Gen-Probe may be unable to meet Chiron's forecasted demand as specified in
an amended Forecast permitted under Section 6.3.1(a)(iv), Gen-Probe shall
promptly provide written notice of such fact to Chiron's Director of Global
Supply Chain Management and Gen-Probe's Vice-President of Manufacturing - Blood
Products. Chiron's Director of Global Supply Chain Management and Gen-Probe's
Vice-President of Manufacturing - Blood Products shall meet and attempt to agree
upon a resolution, including exploring ways to meet such increased demand. If
the parties cannot agree on such a resolution, then the issue will be referred
to the Supervisory Board for resolution no later than the latter of (i) thirty
(30) days after such referral, or (ii) the next regularly scheduled Supervisory
Board meeting. If the Supervisory Board fails to resolve the issue, the parties
may invoke the provisions of Article 13 herein. The failure of Gen-Probe to
supply that quantity of Blood Screening Assays in a Chiron Purchase Order in
excess of Chiron's forecasted demand as specified in the then-current Forecast
or amended Forecast, as permitted under Section 6.3.1(a)(iv) for such month,
shall not trigger the Chiron manufacturing rights set forth in Section 3.2.4(b)
of the Agreement.

            (b)   Gen-Probe shall ensure that the expiration date for Blood
Screening Assays supplied to Chiron shall be no earlier than (i) eleven (11)
months after the date of delivery into warehouse inventory if designated for
export; and (ii) eight (8) months after the date of delivery into warehouse
inventory if designated for delivery in the United States. This provision only
applies to Lots of Blood Screening Assays manufactured after the Amendment
Effective Date (i.e., Lot 13 and beyond).

            (c)   The minimum expiration dating requirement set forth in Section
6.3.5(b) exclude controls, [***] and [***]. The parties will set dating
requirements for these products on or prior to June 30, 2002.

      6.3.6 Warehouse/Distribution Support for Order Processing. During the term
that Gen-Probe provides warehousing support under Section 6.4.4 of this
Agreement, Gen-Probe will provide reasonable staff support to Chiron, such staff
to be responsible for order packing and processing in connection with the sales
of Blood Screening Assays by Chiron. As of the Amendment Effective Date, such
support is estimated to be [***]. Changes to the number of Gen-Probe full-time
equivalent employees necessary to support order packing and processing shall
have no effect on this Agreement, but Gen-Probe will give Chiron reasonable
notice of such changes. Such employee(s) shall be responsible for (i) completing
order processing (including order packing and confirmations of shipment to
Chiron), (ii) maintaining files for special customer requirements, if any, and a
history of shipments for Chiron, (iii) maintaining familiarity with part numbers
and master lot requirements for Blood Screening Assays, and (iv) communicating
regularly with Chiron on Purchase Orders and shipments, recording/reporting
status of shipments, problem fact finding, and resolution of order and/or
shipment problems."

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                                 6
<PAGE>
     3.   DELIVERY. Section 6.4.1 of the Agreement is hereby deleted and
replaced in its entirety by the following:

          "6.4.1    Delivery.

                    (a)  For so long as Gen-Probe provides the warehousing
     support under Section 6.4.4, all Blood Screening Assays purchased by Chiron
     under this Agreement shall be transferred to the warehouse location more
     particularly described in Section 6.4.4 without shipping charges to Chiron.
     Chiron shall be responsible for the cost of shipment out of such warehouse
     facility to any other location, including to Chiron Customers.

                    (b)  At such time as Gen-Probe no longer provides the
     warehousing support under Section 6.4.4, all Blood Screening Assays
     purchased by Chiron under this Agreement shall be shipped f.o.b. place of
     manufacture to such location as designated by Chiron in the applicable
     Purchase Order. Chiron shall have the right to select the carrier.

                    (c)  Chiron shall be responsible for all freight, insurance
     charges, taxes, import and export duties, inspection fees and other charges
     applicable to the sale and transport of Blood Screening Assays purchased by
     Chiron (i) for transfer out of the warehouse to Customers, during the
     period that Gen-Probe provides the warehousing support under Section 6.4.4
     and (ii) to such location designated by Chiron in the applicable Purchase
     Order, at such time as Gen-Probe no longer provides the warehousing support
     under Section 6.4.4. Gen-Probe shall, to the extent possible, charge such
     expenses to Chiron's carrier accounts or pre-pay such charges. When
     Gen-Probe pre-pays such charges, it shall invoice such charges to Chiron in
     reasonable detail, specifying the Blood Screening Assays to which such
     charges apply. Chiron shall pay all such invoices within thirty (30) days
     of date of invoice.

                    (d)  When Blood Screening Assays are shipped from the
     Gen-Probe warehouse, the dry ice fee of [***] for each shipping box
     containing frozen material is a freight charge to be prepaid by Gen-Probe,
     and for which Gen-Probe shall invoice Chiron. The dry ice fee, as well as
     the other charges enumerated in Sections 6.4.1(a) and (c) above shall be
     deducted from the gross sales price of Blood Screening Assays as set forth
     in Section 1.46 herein."

     4.   WAREHOUSING. The following new Section 6.4.4 is hereby added to the
end of Section 6.4 of the Agreement:

          "6.4.4    Warehousing.

                    (a)  Gen-Probe shall provide warehouse capability for Blood
     Screening Assays after sale to Chiron, in accordance with the provisions of
     this Section 6.4.4. Chiron may notify Gen-Probe in writing at any time
     after June 30, 2002 or earlier upon the breach by Gen-Probe of any of its
     obligations under this Section 6.4.4, of its intention to assume the
     warehousing function internally. Such notice shall indicate a date not less
     than 30 days after the date of such notice on which Chiron will assume the
     warehousing function. Gen-Probe may notify Chiron in writing on or before
     November 1 of any year during the term hereof of its decision to terminate
     its provision of the warehouse capabilities described in this Section 6.4.4
     and inventory management described in Section 6.4.5, effective January 1 of
     the immediately succeeding year."

                    (b)  Gen-Probe shall provide adequate warehouse storage at
     its Willow Court facility for all Blood Screening Assays purchased by
     Chiron prior to delivery of such Blood Screening Assays to Chiron or
     Chiron's Customer. Such storage services shall include, as applicable based
     on the type of Blood Screening Assay, frozen, refrigerated, and ambient
     physical storage space. Gen-Probe shall maintain appropriate safety and
     security systems for such storage

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                       7
<PAGE>
space, including monitoring of frozen and cold facilities and providing
appropriate backup systems, in accordance with applicable state and federal
regulations.

          (c)  Gen-Probe shall maintain frozen inventoried Blood Screening
Assays in core-packs, unless otherwise agreed by the parties in writing.

          (d)  During the period in which Gen-Probe is providing warehousing
storage services to Chiron under this Section 6.4.4, Gen-Probe shall segregate,
as appropriate, any Blood Screening Assays being warehoused for Chiron pursuant
to this Section 6.4.4 and identify such Blood Screening Assays as Chiron's
property. Except as otherwise permitted in this Agreement, Gen-Probe shall not,
and shall not permit any third party to, sell, assign, pledge, encumber,
dispose of, or suffer a lien or encumbrance upon or against any interest in the
Blood Screening Assays held by Gen-Probe pursuant to this Section 6.4.4.

          (e)  Gen-Probe shall provide Chiron with information regarding all
transfers to Chiron, and Chiron shall track and maintain inventory in Chiron's
accounting system for all Blood Screening Assays held by Gen-Probe under this
Section 6.4.4. The parties shall cooperate in good faith in the performance of
a periodic inventory reconciliation between Chiron's records and a physical
count to be conducted on all Blood Screening Assays held by Gen-Probe pursuant
to this Section 6.4.4. Such reconciliation shall be conducted once every other
month, unless otherwise agreed to by the parties in writing. In the event that
such reconciliation identifies discrepancies, the parties shall investigate in
good faith the cause of such discrepancies. Each party shall rectify, at its
expense, any discrepancies identified which result from such party's failure to
act in accordance with the terms of this Agreement or reasonable business
practices. If a discrepancy cannot be attributed to either party, then
Gen-Probe shall rectify such discrepancy at its expense.

          (f)  For so long as Gen-Probe provides warehousing support under this
Section 6.4.4 and for as long thereafter as necessary to cover claims
resulting from such warehousing support, Chiron shall maintain: (1) product
liability and general commercial liability insurance having a limit of not less
than [***]; and (2) property damage insurance at replacement value for the
Blood Screening Assays located at Gen-Probe's warehousing facility, pursuant to
one or more insurance policies with reputable insurance carriers.  Chiron
hereby waives subrogation for the benefit of Gen-Probe with respect to the
physical loss of such Blood Screening Assays, except for losses due to the
negligence of Gen-Probe or a breach of Gen-Probe's obligations under this
Section 6.4.4. Chiron shall not cause or permit such insurance to be cancelled
or modified to materially reduce its scope or limits of coverage for so long as
Gen-Probe is providing warehousing support described in Section 6.4.4 or
thereafter as provided above.

          (g)  For so long as Gen-Probe provides warehousing support under this
Section 6.4.4 and for so long thereafter as necessary to cover claims resulting
from such warehousing support, Gen-Probe shall maintain commercial general
liability insurance in the amount of [***], including bailee's legal liability,
and Chiron shall be designated as an "additional insured" as respects its
rights under this Section 6.4.4. Gen-Probe shall maintain such other types of
insurance, with appropriate limits of liability, that are usual and customary
for the nature of Gen-Probe's warehousing operations pursuant to this Section
6.4.4. Gen-Probe shall not cause or permit such insurance to be cancelled or
modified to materially reduce its scope or limits of coverage for so long as
Gen-Probe is providing warehousing support described in Section 6.4.4 or
thereafter as provided above.

          (h)  Chiron shall be permitted reasonable access to Blood Screening
Assays held by Gen-Probe pursuant to this Section 6.4.4 during Gen-Probe's
normal business hours and upon reasonable notice to Gen-Probe. Chiron shall
retain the right to remove from Gen-Probe's

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                       8
<PAGE>
warehouse facility all or any portion of the Blood Screening Assays held by
Gen-Probe pursuant to this Section 6.4.4, upon reasonable advance notice to
Gen-Probe.

                  (i) Gen-Probe shall have the right to require Chiron to
      dispose of, or otherwise remove from Gen-Probe's warehousing facility, any
      and all Blood Screening Assays stored by Gen-Probe pursuant to this
      Section 6.4.4 of which the expiration date has passed.

                  (j) Except for any losses resulting from the negligence of
      Gen-Probe or a breach of Gen-Probe's obligations under this Section 6.4.4,
      Chiron shall bear all risk of loss or damage with respect to the Blood
      Screening Assays once purchased by Chiron, whether located at Gen-Probe's
      warehousing facility or elsewhere.

                  (k) Gen-probe agreed in Supplemental Agreement to provide the
warehouse capabilities described in this Section 6.4.4 and inventory management
described in Section 6.4.5 for a period commencing on January 1, 2001 through
December 31, 2001, and further agreed in the Settlement Agreement to extend the
provision of those services through December 31, 2002, subject to the right of
Gen-Probe to increase the charge for those services as limited by the CPI
described in Section 6.4.5(e).

      5. INSURANCE CERTIFICATES.

            5.1 Unless previously provided to Gen-Probe by Chiron, concurrent
with the execution of this Amendment No. 3, Chiron shall deliver to Gen-Probe
certificates evidencing the insurance referred to in Section 6.4.4(g) of the
Agreement, as amended by this Amendment No. 3.

            5.2 Unless previously provided to Chiron by Gen-Probe, concurrent
with the execution of this Amendment No. 3, Gen-Probe shall deliver to Chiron
certificates evidencing the insurance referred to in Section 6.4.4(h) of the
Agreement, as amended by this Amendment No. 3.

      6. INVENTORY MANAGEMENT. The following new Section 6.4.5 is hereby added
to the end of Section 6.4, following newly added Section 6.4.4:

            "6.4.5 Inventory Management: For so long as Gen-Probe is providing
      the warehousing support services described under Section 6.4.4, the
      following additional provisions shall apply:

                  (a) Gen-Probe will provide necessary staff support to Chiron,
      such staff to be responsible, as described below, for inventory management
      and shipping of Blood Screening Assays from Gen-Probe's San Diego
      facilities as required under this Agreement. As of the Amendment Effective
      Date, such necessary staff is estimated to be [***] employees. Changes in
      the number of full-time equivalent employees necessary to support
      inventory management shall have no effect on this Agreement, but Gen-Probe
      will give Chiron reasonable notice of such changes.

                  (b) Gen-Probe shall, through the services of the support staff
      designated under Section 6.4.5(a) above, provide the following services to
      Chiron:

                        (i) Inventory management of all inventory, including
      reagents, Blood Screening Instruments and parts, packing and shipping
      materials, etc.;

                        (ii) Packing of kitted components, including
      verification of all kitted components to work order, transfer of kitted
      components into shipping containers, application of dry ice, gel packs,
      etc. as required and final assembly and quality control of shipping
      containers;

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                       9

<PAGE>
                    (iii)   Arrangement of and handling transfer to freight
forwarders of all shipments of reagents, ancillaries (TTU, TTC, sealing cards,
etc.) and Blood Screening Instruments, using Chiron's carrier accounts for
freight charges;

                    (iv)    Entry of all appropriate system transactions to
process shipments, including material issue transactions, printing and
application of shipping labels and packing slips;

                    (v)     Completion of shipping paperwork, including freight
bills and/or SLI's, dangerous goods forms and maintenance of records; and

                    (vi)    Interaction with carriers, including pre-arranging
pick-ups, faxing of paperwork to carriers and Chiron to reserve appropriate
space on flights, loading carrier upon arrival, forwarding all paperwork to
appropriate finance and record-keeping personnel, performing any post-shipment
follow-up to ensure timely delivery, informing interested parties of results,
and investigating any post-shipment problems such as flight delays, orders
canceled prior to pick-up, product returns, etc.

               (c)  Gen-Probe will be responsible for arranging direct shipments
to Customers located in the United States. With respect to shipments outside the
United States, Gen-Probe shall only be responsible for arranging shipments to
Chiron's primary foreign distribution points (where such Chiron distribution
points exist), not to exceed one such distribution point per country.

               (d)  When Chiron desires that Blood Screening Assays be shipped
to a Customer out of Chiron's inventory held by Gen-Probe under Section 6.4.4,
Chiron will provide Gen-Probe with a shipping request. Each shipping request
shall be in writing and in a form mutually agreeable to Chiron and Gen-Probe.
Gen-Probe will use Commercially Reasonable Efforts to ship Blood Screening
Assays so that the Blood Screening Assays will arrive at the designated Customer
location by the delivery date set forth in such request, at Chiron's expense.
Gen-Probe will give special attention to emergency orders, but shall not be in
breach of such obligation if Gen-Probe has used Commercially Reasonable Efforts
to expedite shipment for such emergency orders.

               (e)  Chiron shall pay to Gen-Probe a monthly fee of [***] for the
warehousing services rendered by Gen-Probe pursuant to Section 6.4.4 and the
inventory management services described in this Section 6.4.5. Gen-Probe shall
have the right to invoice Chiron, and payment to Chiron will be due on the fifth
(5th) day of each month. Gen-Probe shall have the right to increase such monthly
fee once in each twelve month period, provided, that (i) the increase for the
period January 1 through December 31, 2002 shall not exceed an amount equal to
[***] multiplied by a fraction (1) the numerator of which is the index number in
the Consumer Price Index for the Standard Metropolitan Statistical Area (or
equivalent) that then includes San Diego, California, as published by the U.S.
Department of Labor or other authoritative federal government agency, for
October 1, 2001 and (2) the denominator of which is said index number for
October 1, 2001 and (ii) increases in such monthly fees for periods subsequent
to December 31, 2002 shall be limited in this same fashion. Payments that are
past-due under this Section shall bear a late payment charge at the lesser of
the London Interbank Offered Rate (LIBOR) or the highest rate permitted by
applicable law."

               (f)  Promptly following any termination of the provisions of
warehousing support services described under Section 6.4.4, the parties will
meet to consider the reduced inventory management, packing and shipping needs of
Chiron, and amend this Section 6.4.5 accordingly."

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                       10

<PAGE>
     7.     SAFETY STOCKS. Section 6.12 (Safety Stocks) is hereby deleted and
replaced, in its entirety, as follows:

     "6.12  Safety Stocks.

            (a)   The Supervisory Board will from time-to-time review and
     establish the appropriate level of Safety Stocks for the Blood Screening
     Assays. The parties agree that the appropriate level of Safety Stock for
     the Initial Blood Screening Assay as of the Amendment Effective Date is
     reflected in the five month inventory requirement described in Section
     6.3.4 above.

            (b)   With respect to any Initial Blood Screening Assay or Future
     Blood Screening Assay, the objective of the parties is to share equally the
     aggregate cost of maintaining safety stocks of raw components, work in
     progress, and finished goods as required by CBER."

     8.     SCOPE OF AMENDMENT NO. 3. The parties hereto agree that the
Forecasts and Orders provisions set forth in Section 2 of this Amendment No. 3
address the rights and obligations of each party with respect to Lot 13 and
subsequent Lots. Except as expressly stated herein, nothing in Section 2 of this
Amendment No. 3 shall apply in any respect to the rights or obligations of the
parties with respect to Lots 1-12. Accordingly, and for ease of implementation,
the parties agree that the Forecast and Orders provisions set forth in Section 2
will apply commencing with and applying to the Forecast due April 1, 2002 from
Chiron (covering the 12 months ending April 30, 2003). Notwithstanding the
above, the Order Processing provisions of new Section 6.3.6 shall govern the
rights and obligations of each party from and after the Amendment Effective
Date. Except as set forth in this Section 8, from and after the Amendment
Effective Date, this Amendment No. 3 shall apply in all respects to the
Agreement.

     9.   LIMITED TERMS APPLICABLE TO [***]. The parties agree to equally share
the "variable manufacturing cost" of those portions of [***] held in inventory
by Gen-Probe and Chiron that are unsold, not retained for R&D or other internal
purpose by either party and scrapped due to product expiration, net of the
aggregate purchase price previously paid by Chiron to Gen-Probe for expired
units held in Chiron's inventory. For the purpose of this Amendment No. 3, [***]
will be used as the "variable manufacturing cost" to value scrap material. To
the extent necessary to avoid product outdating and if requested by Chiron,
Gen-Probe agrees to re-label, at Gen-Probe's expense and in accordance with all
international and domestic labeling requirements, such Blood Screening Assays in
[***] that may be relabeled with twenty-four (24) expiration dates.

    10.   EFFECT OF AMENDMENT NO. 3 ON SUPPLEMENTAL AGREEMENT. As of the
Amendment Effective Date, the Supplemental Agreement shall terminate in all
respects. Each party's obligations under such Supplemental Agreement shall
terminate as of such date; provided, however, that such termination shall not
act to bar claims under the terms of the Supplemental Agreement that arose
prior to such Amendment Effective Date.

    11. NO OTHER AMENDMENT. Except as expressly set forth in this Amendment No.
3, all other terms and conditions of the Agreement and the Settlement Agreement
are hereby ratified and shall continue in full force and effect.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       11

<PAGE>

      12.   COUNTERPARTS. This Amendment No. 3 may be executed in counterparts,
each of which shall be deemed an original, and all of which together shall
constitute one and same instrument.

      IN WITNESS WHEREOF, the parties have caused this Amendment No. 3 to be
executed as of April 1, 2002 and the persons signing below warrant that they
are duly authorized to sign for and on behalf of the respective parties.

Gen-Probe:                                Chiron:

GEN-PROBE INCORPORATED,                   CHIRON CORPORATION
a Delaware corporation                    a Delaware corporation

By /s/ HENRY L. NORDHOFF                  By /s/ WILLIAM G. GREEN
   -----------------------------------       -----------------------------------
   Henry L. Nordhoff                         William G. Green
   President and Chief Executive Officer     Senior Vice President and
                                             President, Blood Testing

   [SEAL]

                                       12

<PAGE>

                                  Schedule A.1

                             Labeling Requirements

<Table>
<Caption>
PART
NUMBER            DESCRIPTION                         LABEL OPTIONS
------            -----------                         -------------
<S>               <C>                                 <C>

                                     [***]

</Table>

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.
<PAGE>

                                  SCHEDULE A.2

                Standing Agenda for Production Planning Meetings

Purpose:

Review Forecast and production plan and make the appropriate production
planning and inventory management decisions to meet Customer supply needs in a
cost efficient manner.

Agenda:

      -     Review previous month performance

      -     Shipments

      -     Inventory

      -     Production

      -     Delivery

      -     Review current Forecast and production plan

      -     [***]

      -     Timing/feasibility for next production?

      -     "What If analysis" - Risk and risk management discussion

      -     Outstanding issues [***]

      -     Review Plan and Key Decisions.

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.
<PAGE>
                                  Schedule A.3

                             Sample Purchase Order
<PAGE>
<TABLE>
<S><C>
------------------------
     PURCHASE ORDER                        SUPPLIER:
------------------------                   GEN-PROBE INCORPORATED                            CHIRON
P.O.# 45059813                             10210 GENETIC CENTER DRIVE
Order Date: 21-May-2002                    SAN DIEGO CA  92121
Buyer: Mary Semeniuk
Phone #: 510-923-6010                      Vendor Contact: SHERYL STILES
Fax #: 510-923-3340                        Phone #: 858-410-8984
                                           Fax #: 800-288-3141
------------------------

A copy of this purchase order was faxed to Sheryl Stiles at Gen-Probe.

Equal Opportunity Contract Clause (EOC)
Chiron Corporation is committed to the provisions outlined
in the Equal Opportunity Clauses of Executive Order 11246,
(60-1.4), Section 503 of the Rehabilitation Act of 1973,
(60-741.5), and, Section 402 of the Vietnam Veterans
Readjustment Act of 1974, (60-250.4), As well as any other                               ----------
regulations pertaining to these orders.                                                    SAMPLE
                                                                                         ----------
Please fax a copy of the packing list to Erica Artis at Chiron Corp at 510-923-2786.

-----------------------------------------------------------------------------------------------------
Item #     QTY/UOM     Chiron Mat#                                     Price         Extended Price
                       Vendor Mat#
                       Material Description
-----------------------------------------------------------------------------------------------------
   1        170 EA     [***]                                        [***] per EA          [***]

                       301030-PROCLEIX (TM), 5000 IVD TEST KIT
                       [***]
                       [***]

   2         35 EA     [***]                                        [***] per EA          [***]
                       301031
                       301031-PROCLEIX (TM), 1000 IVD TEST KIT
                       [***]
                       [***]

   3        885 EA     [***]                                        [***] per EA          [***]

                       301027-PROCLEIX (TM), ASSAY FLUIDS, IVD
                       [***]
                       [***]

   4        443 EA     [***]                                        [***] per EA          [***]

                       301038-PROCLEIX (TM), AUTO DETECT, IVD
                       [***]
                       [***]
</TABLE>

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                                                     Page 1 of 3
<PAGE>
<TABLE>
<S><C>
------------------------
     PURCHASE ORDER                        SUPPLIER:
------------------------                   GEN-PROBE INCORPORATED                            CHIRON
P.O.# 45059813                             10210 GENETIC CENTER DRIVE
Order Date: 21-May-2002                    SAN DIEGO CA  92121
Buyer: Mary Semeniuk
Phone #: 510-923-6010                      Vendor Contact: SHERYL STILES
Fax #: 510-923-3340                        Phone #: 858-410-8984
                                           Fax #: 800-288-3141
------------------------
                                                                                         ----------
                                                                                           SAMPLE
                                                                                         ----------

-----------------------------------------------------------------------------------------------------
Item #     QTY/UOM     Chiron Mat#                                     Price         Extended Price
                       Vendor Mat#
                       Material Description
-----------------------------------------------------------------------------------------------------
   5        575 EA     [***]                                        [***] per EA          [***]

                       301026-PROCLEIX (TM), DISCR PROBE, IVD
                       [***]

   6         60 EA     [***]                                        [***] per EA          [***]
                       301036
                       301036-PROCLEIX (TM),HIV-1/HCV CALIB,IVD
                       [***]

   7        465 EA     [***]                                        [***] per EA          [***]
                       301035
                       301035-PROCLEIX (TM),HIV-1/HCV CONTR,IVD
                       [***]

   8         50 EA     [***]                                        [***] per EA          [***]
                       301034
                       301034-PROCLEIX (TM), PROF PANELS, IVD
                       [***]

   9        885 CAS    [***]                                        [***] per CAS         [***]
                       GP
                       TU0022-TEN TUBE UNIT (TTU), ESAS
                       [***]

  10        885 CAS    [***]                                        [***] per CAS         [***]
                       GP
                       104578-TEN TUBE CASSETTE (TTC)
                       [***]

  11      7,630 CAS    [***]                                        [***] per CAS         [***]
                       GP
                       102085-SEALING CARDS (35/PKG)
                       [***]

  12         38 EA     [***]                                        [***] per EA          [***]
                       [***]
                       [***]

</TABLE>

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                                                     Page 2 of 3
<PAGE>
<TABLE>
<S><C>
------------------------
     PURCHASE ORDER                        SUPPLIER:
------------------------                   GEN-PROBE INCORPORATED                            CHIRON
P.O.# 45059813                             10210 GENETIC CENTER DRIVE
Order Date: 21-May-2002                    SAN DIEGO CA  92121
Buyer: Mary Semeniuk
Phone #: 510-923-6010                      Vendor Contact: SHERYL STILES
Fax #: 510-923-3340                        Phone #: 858-410-8984
                                           Fax #: 800-288-3141
------------------------
                                                                                         ----------
                                                                                           SAMPLE
                                                                                         ----------

-----------------------------------------------------------------------------------------------------
Item #     QTY/UOM     Chiron Mat#                                     Price         Extended Price
                       Vendor Mat#
                       Material Description
-----------------------------------------------------------------------------------------------------

                       DELIVERY DATE: [***]

-----------------------------------------------------------------------------------------------------
                                 TOTAL NET ITEM VALUE EXCLUDING TAX                     [***] USD

Free on board SHIPPING POINT
Payment Terms: Within 30 days Due net

REMIT TO:                                                  DELIVER TO:

Chiron Corporation                                         Chiron Warehouse
Accounts Payable Department                                C/O Gen-Probe Incorporated
4560 Horton Street                                         10808 Willow Court
Emeryville, CA 94608                                       San Diego, CA 92127
Attn: P.O.#45059813                                        Attn: P.O.# 45059813

Supplier Confirmation By:                                  For Chiron Corp. By:
(If Requested)            -----------------------------                          -----------------------------
                          Authorized Agent, Title, Date                          Authorized Agent, Title, Date

</TABLE>

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                                                     Page 3 of 3
<PAGE>

                                  Schedule A.4

                         List of Warehousing Facilities

Gen-Probe Incorporated
10808 Willow Court
San Diego, California 92127
United States

BOMI France Snc
Rue de la Maison Rouge
Parc d'activities Paris East
77185 Lognes
France

Dade Berhring Diagnostics Pty Ltd
Orion Road 18-20
2066 Lane Cove
New South Wales, Australia

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]